Effect of Epigenetic Treatment on SST Expression in Neuroendocrine Tumour Patients

Overview

Journal Clin Transl Med

Publisher Wiley

Specialty General Medicine

Date 2022 Jul 22

PMID 35866246

Authors

Julie Refardt

Maria J Klomp

Peter M Van Koetsveld

Fadime Dogan

Mark Konijnenberg

Tessa Brabander

Richard A Feelders

Wouter W de Herder

Leo J Hofland

Johannes Hofland

Affiliations

Soon will be listed here.

Citing Articles

Improving susceptibility of neuroendocrine tumors to radionuclide therapies: personalized approaches towards complementary treatments.

Richter S, Steenblock C, Fischer A, Lemm S, Ziegler C, Bechmann N Theranostics. 2024; 14(1):17-32.

PMID: 38164150 PMC: 10750207. DOI: 10.7150/thno.87345.

The role of DNA methylation in human pancreatic neuroendocrine tumours.

English K, Thakker R, Lines K Endocr Oncol. 2023; 3(1):e230003.

PMID: 37434653 PMC: 10305641. DOI: 10.1530/EO-23-0003.

Epigenetic regulation of SST expression in small intestinal neuroendocrine tumors.

Klomp M, Refardt J, Van Koetsveld P, Campana C, Dalm S, Dogan F Front Endocrinol (Lausanne). 2023; 14:1184436.

PMID: 37223009 PMC: 10200989. DOI: 10.3389/fendo.2023.1184436.

Up-Regulation of PSMA Expression In Vitro as Potential Application in Prostate Cancer Therapy.

Runge R, Naumann A, Miederer M, Kotzerke J, Brogsitter C Pharmaceuticals (Basel). 2023; 16(4).

PMID: 37111295 PMC: 10144194. DOI: 10.3390/ph16040538.

Epigenetic drugs in somatostatin type 2 receptor radionuclide theranostics and radiation transcriptomics in mouse pheochromocytoma models.

Ullrich M, Richter S, Liers J, Drukewitz S, Friedemann M, Kotzerke J Theranostics. 2023; 13(1):278-294.

PMID: 36593963 PMC: 9800739. DOI: 10.7150/thno.77918.

References

Zambrano P, Segura-Pacheco B, Perez-Cardenas E, Cetina L, Revilla-Vazquez A, Taja-Chayeb L . A phase I study of hydralazine to demethylate and reactivate the expression of tumor suppressor genes. BMC Cancer. 2005; 5:44. PMC: 1131894. DOI: 10.1186/1471-2407-5-44. View

Menda Y, Ponto L, Schultz M, Zamba G, Watkins G, Bushnell D . Repeatability of gallium-68 DOTATOC positron emission tomographic imaging in neuroendocrine tumors. Pancreas. 2013; 42(6):937-43. PMC: 3898770. DOI: 10.1097/MPA.0b013e318287ce21. View

Taelman V, Radojewski P, Marincek N, Ben-Shlomo A, Grotzky A, Olariu C . Upregulation of Key Molecules for Targeted Imaging and Therapy. J Nucl Med. 2016; 57(11):1805-1810. DOI: 10.2967/jnumed.115.165092. View

Pollard J, Menda Y, Zamba K, Madsen M, ODorisio M, ODorisio T . Potential for Increasing Uptake of Radiolabeled Ga-DOTATOC and I-MIBG in Patients with Midgut Neuroendocrine Tumors Using a Histone Deacetylase Inhibitor Vorinostat. Cancer Biother Radiopharm. 2021; 36(8):632-641. PMC: 8817731. DOI: 10.1089/cbr.2020.4633. View

Veenstra M, Van Koetsveld P, Dogan F, Farrell W, Feelders R, Lamberts S . Epidrug-induced upregulation of functional somatostatin type 2 receptors in human pancreatic neuroendocrine tumor cells. Oncotarget. 2018; 9(19):14791-14802. PMC: 5871078. DOI: 10.18632/oncotarget.9462. View

Duenas-Gonzalez A, Coronel J, Cetina L, Gonzalez-Fierro A, Chavez-Blanco A, Taja-Chayeb L . Hydralazine-valproate: a repositioned drug combination for the epigenetic therapy of cancer. Expert Opin Drug Metab Toxicol. 2014; 10(10):1433-44. DOI: 10.1517/17425255.2014.947263. View

Refardt J, Zandee W, Brabander T, Feelders R, Franssen G, Hofland L . Inferior outcome of neuroendocrine tumor patients negative on somatostatin receptor imaging. Endocr Relat Cancer. 2020; 27(11):615-624. DOI: 10.1530/ERC-20-0340. View

Klomp M, Dalm S, Van Koetsveld P, Dogan F, de Jong M, Hofland L . Comparing the Effect of Multiple Histone Deacetylase Inhibitors on SSTR2 Expression and [In]In-DOTATATE Uptake in NET Cells. Cancers (Basel). 2021; 13(19). PMC: 8508045. DOI: 10.3390/cancers13194905. View

Candelaria M, Burgos S, Ponce M, Espinoza R, Duenas-Gonzalez A . Encouraging results with the compassionate use of hydralazine/valproate (TRANSKRIP™) as epigenetic treatment for myelodysplastic syndrome (MDS). Ann Hematol. 2017; 96(11):1825-1832. DOI: 10.1007/s00277-017-3103-x. View

10.

Geenen L, Nonnekens J, Konijnenberg M, Baatout S, de Jong M, Aerts A . Overcoming nephrotoxicity in peptide receptor radionuclide therapy using [Lu]Lu-DOTA-TATE for the treatment of neuroendocrine tumours. Nucl Med Biol. 2021; 102-103:1-11. DOI: 10.1016/j.nucmedbio.2021.06.006. View